Flutamide

Generic Name: Flutamide

Brand Names: Eulexin

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₁F_₃N_₂O_₃

CAS Number: 13311-84-7

Unique Ingredient Identifier: 76W6J0943E

Background: An antiandrogen with about the same potency as cyproterone in rodent and canine species.

Indication: For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate

Associated Conditions: Stage B2-C metastatic Carcinoma of the Prostate, Stage D2 metastatic Carcinoma of the Prostate

Associated Therapies: -

Clinical Trials

Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

First Posted Date: 2008-10-07

Last Posted Date: 2014-01-28

Lead Sponsor: Radiation Therapy Oncology Group

Registration Number: NCT00767286

Effects of Flutamide on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome

Not Applicable

Terminated

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: Placebo
Drug: Flutamide

First Posted Date: 2008-08-07

Last Posted Date: 2014-09-08

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 8

Registration Number: NCT00729560

Locations: 🇺🇸
Virginia Commonwealth University General Clinical Research Center, Richmond, Virginia, United States

Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: flutamide

First Posted Date: 2008-06-18

Last Posted Date: 2018-07-24

Lead Sponsor: University of Arizona

Target Recruit Count: 127

Registration Number: NCT00699907

Locations: 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States

Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: buserelin
Drug: flutamide
Drug: goserelin
Drug: leuprolide acetate
Procedure: neoadjuvant therapy
Procedure: quality-of-life assessment
Radiation: radiation therapy
Drug: Docetaxel

First Posted Date: 2008-04-02

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 48

Registration Number: NCT00651326

Locations: 🇨🇦
McGill University - Dept. Oncology, Montreal, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Canada

and more 10 locations

Effectiveness of Flutamide in Treating Women With Premenstrual Dysphoric Disorder

Phase 4

Completed

Conditions: Premenstrual Syndrome

Interventions: Drug: Placebo
Drug: Flutamide

First Posted Date: 2008-02-11

Last Posted Date: 2020-01-07

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 115

Registration Number: NCT00611923

Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: docetaxel
Drug: flutamide
Drug: LHRH agonist
Radiation: 3-dimensional conformal radiation therapy
Radiation: radiation therapy

First Posted Date: 2007-09-12

Last Posted Date: 2019-04-24

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 80

Registration Number: NCT00528866

Locations: 🇺🇸
Mary Bird Perkins Cancer Center - Baton Rouge, Baton Rouge, Louisiana, United States
🇺🇸
Mercy Cancer Center at Mercy San Juan Medical Center, Carmichael, California, United States
🇺🇸
Fox Chase Cancer Center CCOP Research Base, Philadelphia, Pennsylvania, United States

and more 67 locations

Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer

Phase 1

Terminated

Conditions: Adenocarcinoma of the Prostate
Recurrent Prostate Cancer

Interventions: Drug: leuprolide acetate
Drug: goserelin acetate
Drug: bicalutamide
Drug: nilutamide
Drug: flutamide
Drug: temsirolimus
Other: laboratory biomarker analysis

First Posted Date: 2007-08-08

Last Posted Date: 2013-01-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00512668

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Metabolic Syndrome in PCOS: Precursors and Interventions

Not Applicable

Completed

Conditions: Polycystic Ovary Syndrome
Metabolic Syndrome

Interventions: Drug: ethinyl estradiol 35 mcg and drospirenone 3 mg
Other: placebo
Drug: flutamide

First Posted Date: 2007-03-02

Last Posted Date: 2014-06-06

Lead Sponsor: Northwestern University

Target Recruit Count: 97

Registration Number: NCT00442689

Locations: 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States

External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Procedure: Radiation Therapy
Behavioral: Questionnaire
Drug: Bicalutamide
Drug: Leuprolide
Drug: Goserelin
Drug: Flutamide

First Posted Date: 2006-10-17

Last Posted Date: 2012-08-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT00388804

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Flutamide
Drug: Leuprolide Acetate

First Posted Date: 2005-09-22

Last Posted Date: 2018-08-07

Lead Sponsor: University of Washington

Target Recruit Count: 102

Registration Number: NCT00223665

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy